Shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) traded up 16.3% during trading on Tuesday . The stock traded as high as $15.56 and last traded at $13.61, with a volume of 367,076 shares changing hands. The stock had previously closed at $11.70.

Several analysts have recently commented on the stock. Cowen and Company assumed coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “outperform” rating on the stock. Wedbush assumed coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “outperform” rating and a $18.00 price target on the stock. HC Wainwright assumed coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 18th. They set a “neutral” rating and a $10.00 price target on the stock. JMP Securities assumed coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “outperform” rating and a $22.00 price target on the stock. Finally, Piper Jaffray Cos. assumed coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “overweight” rating and a $20.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $17.50.

The stock’s market cap is $320.22 million. The stock’s 50 day moving average price is $11.59 and its 200 day moving average price is $12.64.

In related news, major shareholder Redmile Group, Llc purchased 432,746 shares of the business’s stock in a transaction on Wednesday, July 6th. The shares were bought at an average price of $12.50 per share, with a total value of $5,409,325.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Nelsen purchased 400,000 shares of the business’s stock in a transaction on Wednesday, July 6th. The shares were bought at an average cost of $12.50 per share, for a total transaction of $5,000,000.00. The disclosure for this purchase can be found here.

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.